The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor

Summary.  Background: Coagulation factor VIII (FVIII) is a heavily glycosylated heterodimeric plasma protein that consists of a heavy (domains A1‐A2‐B) and light chain (domains A3‐C1‐C2). It has been well established that the clearance of FVIII from the circulation involves mechanisms that are sensitive to the low‐density lipoprotein receptor (LDLR) family antagonist receptor‐associated protein (RAP), including LDLR‐related protein. Because FVIII clearance in the presence of a bolus injection of RAP still occurs fairly efficient, also RAP‐independent mechanisms are likely to be involved. Objectives: In the present study, we investigated the interaction of FVIII with the endocytic lectin asialoglycoprotein receptor (ASGPR) and the physiological relevance thereof. Methods and results: Surface plasmon resonance studies demonstrated that FVIII dose‐dependently bound to ASGPR with high affinity (Kd ≈ 2 nm). FVIII subunits were different in that only the heavy chain displayed high‐affinity binding to ASGPR. Studies employing a FVIII variant that lacks the B domain revealed that FVIII‐ASGPR complex assembly is driven by structure elements within the B domain of the heavy chain. The FVIII heavy chain‐ASGPR interaction required calcium ions and was inhibited by soluble d‐galactose. Furthermore, deglycosylation of the FVIII heavy chain by endoglycosidase F completely abrogated the interaction with ASGPR. In clearance experiments in mice, the FVIII mean residence time was prolonged by the ASGPR‐antagonist asialo‐orosomucoid (ASOR). Conclusions: We conclude that asparagine‐linked oligosaccharide structures of the FVIII B domain recognize the carbohydrate recognition domains of ASGPR and that an ASOR‐sensitive mechanism, most likely ASGPR, contributes to the catabolism of coagulation FVIII in vivo.

[1]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[2]  A. Morell,et al.  Physical and chemical studies on ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation. , 1970, The Journal of biological chemistry.

[3]  P. Lenting,et al.  Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. , 1994, The Journal of biological chemistry.

[4]  D. Meijer,et al.  Biliary excretion of FITC metabolites after administration of FITC labeled asialo orosomucoid as a measure of lysosomal proteolysis. , 1985, Biochemical pharmacology.

[5]  Structural study of the sugar chains of porcine factor VIII--tissue- and species-specific glycosylation of factor VIII. , 1993, Archives of biochemistry and biophysics.

[6]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[7]  A. Dorner,et al.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. , 1988, The Journal of biological chemistry.

[8]  T. Willnow,et al.  Lipoprotein receptors: new roles for ancient proteins , 1999, Nature Cell Biology.

[9]  A. Giles,et al.  Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. , 1993, Blood.

[10]  M. Shima,et al.  Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-related Protein* , 2001, The Journal of Biological Chemistry.

[11]  Niels Bovenschen,et al.  Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII* , 2003, The Journal of Biological Chemistry.

[12]  A. Morell,et al.  PHYSICAL AND CHEMICAL STUDIES ON CERULOPLASMIN. 3. A STABILIZING COPPER-COPPER INTERACTION IN CERULOPLASMIN. , 1965, The Journal of biological chemistry.

[13]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[14]  D. Wall,et al.  The galactose-specific recognition system of mammalian liver: The route of ligand internalization in rat hepatocytes , 1980, Cell.

[15]  P. McKeown-Longo,et al.  Circulating cellular fibronectin may be a natural ligand for the hepatic asialoglycoprotein receptor: Possible pathway for fibronectin deposition and turnover in the rat liver , 1998, Hepatology.

[16]  J. Baenziger,et al.  Rapid Clearance of Sialylated Glycoproteins by the Asialoglycoprotein Receptor* , 2003, The Journal of Biological Chemistry.

[17]  P. Lenting,et al.  Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. , 2003, Blood.

[18]  Y. Maynard,et al.  Human hepatic lectin. Physiochemical properties and specificity. , 1980, The Journal of biological chemistry.

[19]  A. Varki,et al.  Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. V. van Berkel,et al.  Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism. , 2003, The Biochemical journal.

[21]  R. Stockert,et al.  The asialoglycoprotein receptor: relationships between structure, function, and expression. , 1995, Physiological reviews.

[22]  T. Griggs,et al.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  I. Mikhailenko,et al.  Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism* , 1999, The Journal of Biological Chemistry.

[24]  P. Mannucci,et al.  Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M) , 1992, Thrombosis and Haemostasis.

[25]  G. Gregoriadis,et al.  The role of sialic acid in determining the survival of glycoproteins in the circulation. , 1971, The Journal of biological chemistry.

[26]  G. Ashwell,et al.  Carbohydrate-specific receptors of the liver. , 1982, Annual review of biochemistry.

[27]  G. Bu,et al.  The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. , 2001, International review of cytology.

[28]  R. Townsend,et al.  Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. , 1983, The Journal of biological chemistry.

[29]  R. Kammerer,et al.  The Oligomerization Domain of the Asialoglycoprotein Receptor Preferentially Forms 2:2 Heterotetramers in Vitro* , 1996, The Journal of Biological Chemistry.

[30]  A. Kobata,et al.  Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. , 1992, The Journal of biological chemistry.

[31]  T. V. van Berkel,et al.  Characterization of the Binding of Urokinase-Type Plasminogen Activator to the Asialoglycoprotein Receptor , 2002, Thrombosis and Haemostasis.

[32]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[33]  K. Mohlke,et al.  Mvwf, a Dominant Modifier of Murine von Willebrand Factor, Results from Altered Lineage-Specific Expression of a Glycosyltransferase , 1999, Cell.

[34]  K. Drickamer,et al.  Selective Sugar Binding to the Carbohydrate Recognition Domains of the Rat Hepatic and Macrophage Asialoglycoprotein Receptors (*) , 1996, The Journal of Biological Chemistry.

[35]  Y. Ling,et al.  Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner. , 1997, Biochemistry.

[36]  K. Huang,et al.  Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.